TY  - JOUR
AU  - Romero, Atocha
AU  - Jantus-Lewintre, Eloisa
AU  - García-Peláez, Beatriz
AU  - Royuela, Ana
AU  - Insa, Amelia
AU  - Cruz, Patricia
AU  - Collazo, Ana
AU  - Pérez Altozano, Javier
AU  - Vidal, Oscar Juan
AU  - Diz, Pilar
AU  - Cobo, Manuel
AU  - Hernández, Berta
AU  - Vázquez Estevez, Sergio
AU  - Benítez, Gretel
AU  - Guirado, Maria
AU  - Majem, Margarita
AU  - Bernabé, Reyes
AU  - Ortega, Ana Laura
AU  - Blasco, Ana
AU  - Bosch-Barrera, Joaquim
AU  - Jurado, Jose M
AU  - García González, Jorge
AU  - Viteri, Santiago
AU  - Garcia Giron, Carlos
AU  - Massutí, Bartomeu
AU  - Lopez Martín, Ana
AU  - Rodriguez-Festa, Alejandro
AU  - Calabuig-Fariñas, Silvia
AU  - Molina-Vila, Miguel Ángel
AU  - Provencio, Mariano
PY  - 2020
DO  - 10.1002/1878-0261.12832
UR  - http://hdl.handle.net/10668/16484
T2  - Molecular oncology
AB  - Several platforms for noninvasive EGFR testing are currently used in the clinical setting with sensitivities ranging from 30% to 100%. Prospective studies evaluating agreement and sources for discordant results remain lacking. Herein, seven...
LA  - en
KW  - NGS
KW  - circulating free DNA
KW  - epidermal growth factor receptor
KW  - non-small-cell lung cancer
KW  - osimertinib
KW  - tyrosine kinase inhibitor
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Biopsy
KW  - Cohort Studies
KW  - DNA Mutational Analysis
KW  - DNA, Neoplasm
KW  - ErbB Receptors
KW  - Exons
KW  - Female
KW  - Gene Frequency
KW  - High-Throughput Nucleotide Sequencing
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Mutation
KW  - Predictive Value of Tests
KW  - Sensitivity and Specificity
KW  - Sequence Deletion
TI  - Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial.
TY  - research article
VL  - 15
ER  -